1. Home
  2. MGLD vs OTLK Comparison

MGLD vs OTLK Comparison

Compare MGLD & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MGLD

The Marygold Companies Inc.

HOLD

Current Price

$1.00

Market Cap

44.8M

Sector

Finance

ML Signal

HOLD

Logo Outlook Therapeutics Inc.

OTLK

Outlook Therapeutics Inc.

HOLD

Current Price

$0.39

Market Cap

38.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MGLD
OTLK
Founded
1996
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
44.8M
38.7M
IPO Year
2021
2016

Fundamental Metrics

Financial Performance
Metric
MGLD
OTLK
Price
$1.00
$0.39
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
$2.50
AVG Volume (30 Days)
71.5K
1.1M
Earning Date
05-27-2026
06-02-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
55.91
EPS
N/A
N/A
Revenue
$34,876,734.00
$8,146,123.00
Revenue This Year
N/A
$1,726.70
Revenue Next Year
N/A
$80.34
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.64
$0.34
52 Week High
$1.38
$3.39

Technical Indicators

Market Signals
Indicator
MGLD
OTLK
Relative Strength Index (RSI) 45.28 39.23
Support Level $0.98 $0.39
Resistance Level $1.08 $0.46
Average True Range (ATR) 0.07 0.03
MACD -0.01 0.01
Stochastic Oscillator 42.31 40.71

Price Performance

Historical Comparison
MGLD
OTLK

About MGLD The Marygold Companies Inc.

The Marygold Companies Inc is an international holding company focused on acquiring and growing profitable businesses. Its main segments include U.S. Fund Management through USCF Investments, Food Products via Gourmet Foods and Printstock Products in New Zealand, Beauty Products under the Original Sprout brand, and formerly Security Systems through Brigadier, sold in 2025. The majority of revenue comes from fund management. The company operates in the USA, New Zealand, the United Kingdom, and Canada, with the majority of revenue generated from the USA. Its business approach focuses on strengthening financial services, expanding fintech, and managing a diverse portfolio for growth.

About OTLK Outlook Therapeutics Inc.

Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.

Share on Social Networks: